Scalzo Richard William 4

What Happened

Richard William Scalzo, Chief Financial Officer of Crescent BioPharma (CBIO), sold 1,112 shares on June 22, 2026. The weighted-average reported price was $17.99, for aggregate proceeds of $20,005. The sale was a disposition (sale) rather than a purchase and was executed to satisfy tax withholding obligations tied to the settlement of restricted stock units.

Key Details

• Transaction type: Sale (reported as S); executed to cover tax withholding (footnote F1 / code F).
• Date of transaction: 2026-06-22; Form 4 filed 2026-06-23 (timely).
• Price: Weighted average $17.99; individual trade prices ranged $16.88–$18.86 (footnote F2).
• Shares sold: 1,112 — total proceeds reported $20,005.
• Plan/authorization: Sold pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026 (per F1).
• Ownership after transaction: Not disclosed in the provided excerpt of the filing.
• Filing accession: 0001628280-26-044890 (for reference).

Context

• This sale was a routine tax-withholding disposition tied to RSU settlement (RSUs granted December 15, 2025) and executed under a 10b5-1 plan — commonly used to automate planned trades and reduce questions about timing. Such sales are typically administrative (to cover taxes) and do not necessarily indicate a change in the insider’s view of the company.